Menarini Expands In Cancer With Radius Drug Deal
Elacestrant Is An Oral SERD In Phase III For Breast Cancer
Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.
You may also be interested in...
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.
A number of companies with marketing applications at the later stages of the EU review process are seeking extra time to address remaining concerns the European Medicines Agency’s drug evaluation committee, the CHMP, has about their filings.